Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Yulia Alexeeva"'
Autor:
Pawef Robak, Victoria Moody, Gabor Mikala, Meletios-Athanasios Dimopoulos, Fredrik Schjesvold, Ivan Spicka, Luděk Pour, Yulia Alexeeva, Galina Salogub, Antonio Lazzaro, Tamás Masszi, Maria-Victoria Mateos, Paul G. Richardson, Vadim A Doronin, Sosana Delimpasi, Daniel Coriu, Catriona Byrne, Vladimir Maisnar, Marcus Thuresson, Wojciech Legiec, Johan Harmenberg, Pieter Sonneveld, Roman Hájek, Jiri Minarik
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S32
Background Melphalan flufenamide (melflufen) is a first-in-class peptide-drug conjugate that targets aminopeptidases and thereby rapidly releases alkylating agents inside tumor cells. Accelerated approval in the United States of melflufen + dex for p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::56d91e5baeb03fcacc2d85d357055697
https://doi.org/10.1016/s2152-2650(21)02124-8
https://doi.org/10.1016/s2152-2650(21)02124-8
Autor:
Darina Zamoeva, Georgy Baratashvili, Alexey Petrov, Andrey Zaritskey, Tatiana Silina, Yulia Alexeeva, Natalia Ilyina, Diana Babenetskaya, Dmitry Motorin, Renat Badaev
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 16:S79-S80
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3339b7e0c525883e954a00553d1f19ed
https://doi.org/10.1016/j.clml.2016.07.111
https://doi.org/10.1016/j.clml.2016.07.111
Autor:
Diana Mescheryakova, Eugenia Sbityakova, Vladimir Strugov, Ekaterina Romanova, Nadia Siordia, Elza Lomaia, Andrey Zaritskey, Tatiana Silina, Elena Goriunova, Larisa Girshova, Yulia Alexeeva, Dmitry Motorin, Natalia Lazorko
Publikováno v:
Blood. 122:5173-5173
Dramatic changes in overall survival of patients (pts) with chronic myeloid leukemia (CML) in chronic phase (CP) have occurred since tyrosine kinase inhibitors (TKIs) were implemented in the treatment strategy. But there are still many issues in ther
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8991f19986d9e7f98ee2221ada7eb123
https://doi.org/10.1182/blood.v122.21.5173.5173
https://doi.org/10.1182/blood.v122.21.5173.5173
Autor:
Ada Braun, Yulia Alexeeva, Arun Balakumaran, Thierry Facon, David Roodman, Evangelos Terpos, Amy Feng, Andrew Spencer, Noopur Raje, A. Keith Stewart, Wolfgang Willenbacher, Vania Hungria
Publikováno v:
Journal of Clinical Oncology. 31:8589-8589
8589 Background: Denosumab (dmab) is a fully human monoclonal antibody against RANKL and is superior to ZA in preventing skeletal-related events (SREs) as shown in 3 identically designed phase 3 trials (N=5723). Overall survival (OS) was balanced bet
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::88cddd6e36dcf24b1fbfb1169e39bc0d
https://doi.org/10.1200/jco.2013.31.15_suppl.8589
https://doi.org/10.1200/jco.2013.31.15_suppl.8589
Autor:
Elena Goryunova, Larisa Girshova, Ekaterina Romanova, Yulia Alexeeva, Tatiana Nikulina, Dmitry Motorin, Andrey Zaritskey
Publikováno v:
Blood. 118:4286-4286
Abstract 4286 AML M-4 with >30% bone marrow myeloblasts was detected in 63 y old woman 2 mo after a diagnosis of chronic myelomonocytic leukemia (CMMLgrade 2). Cytogenetics showed 46, XX, del(5)(q12 q14) (N=4)/46, XX (N=18). Immune-phenotyping sho
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::307f56ae8fb3021ddd6d13691c5f3d9c
https://doi.org/10.1182/blood.v118.21.4286.4286
https://doi.org/10.1182/blood.v118.21.4286.4286